Literature DB >> 19497088

Two unusual bovine spongiform encephalopathy cases detected in Great Britain.

M Stack1, R Focosi-Snyman, S Cawthraw, L Davis, R Jenkins, L Thorne, M Chaplin, S Everitt, G Saunders, L Terry.   

Abstract

Bovine spongiform encephalopathy (BSE) was first identified in Great Britain (GB) in 1986 and was subsequently detected in many other countries, worldwide. A decade after the start of the bovine epidemic, the first cases of new variant Creutzfeldt-Jakob disease (vCJD) in humans were linked to probable ingestion of BSE infected tissue, highlighting a new zoonotic disease. An abnormal protease-resistant protein (PrP(res)) in a diseased subject, derived from a post-translational change of a normal host cellular membrane protein (PrP(c)), is a reliable disease marker for the whole group of neurodegenerative transmissible spongiform encephalopathies (TSEs). Immunology-based techniques, such as Western immunoblotting, have previously indicated that BSE cases all give a uniform molecular profile for PrP(res). Periodic lesion profiling of the spongiform change throughout different brain regions of infected mice and cattle has also indicated a single agent for BSE. However, in 2001 rapid testing for PrP(res) was introduced for the active surveillance of ruminants within Europe, and approximately 40 BSE cases have now been recognized that differ in their molecular profiles from those typically found. These unusual BSE cases have been detected in several European countries, and in Japan and the USA. At present, the cases appear as two distinct types based on the molecular mass (Mm) of the unglycosylated PrP(res) protein band relative to that of classical BSE. One type is of a higher Mm (H-type) and the other shows a lower Mm (L-type). Transmission studies in mice have shown that both H-type and L-type BSE have biological characteristics that are different from those of the classical BSE agent. This study describes the prion protein (PRNP) genotype and molecular profiles of the first two cases of H-type BSE detected in GB in comparison with those obtained for classical BSE, scrapie in sheep from GB and a control H-type BSE case from France.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19497088     DOI: 10.1111/j.1863-2378.2008.01202.x

Source DB:  PubMed          Journal:  Zoonoses Public Health        ISSN: 1863-1959            Impact factor:   2.702


  5 in total

1.  Four independent molecular prion protein parameters for discriminating new cases of C, L, and h bovine spongiform encephalopathy in cattle.

Authors:  Jan P M Langeveld; Jo H F Erkens; Ines Rammel; Jorg G Jacobs; Aart Davidse; Fred G van Zijderveld; Alex Bossers; Hermann Schildorfer
Journal:  J Clin Microbiol       Date:  2011-06-15       Impact factor: 5.948

2.  Clinical and pathologic features of H-type bovine spongiform encephalopathy associated with E211K prion protein polymorphism.

Authors:  Justin J Greenlee; Jodi D Smith; M Heather West Greenlee; Eric M Nicholson
Journal:  PLoS One       Date:  2012-06-08       Impact factor: 3.240

3.  Experimental H-type bovine spongiform encephalopathy characterized by plaques and glial- and stellate-type prion protein deposits.

Authors:  Hiroyuki Okada; Yoshifumi Iwamaru; Morikazu Imamura; Kentaro Masujin; Yuichi Matsuura; Yoshihisa Shimizu; Kazuo Kasai; Shirou Mohri; Takashi Yokoyama; Stefanie Czub
Journal:  Vet Res       Date:  2011-06-23       Impact factor: 3.683

4.  No H- and L-type cases in Belgium in cattle diagnosed with bovine spongiform encephalopathy (1999-2008) aging seven years and older.

Authors:  Alexandre Dobly; Jan Langeveld; Lucien van Keulen; Caroline Rodeghiero; Stéphanie Durand; Riet Geeroms; Patrick Van Muylem; Jessica De Sloovere; Emmanuel Vanopdenbosch; Stefan Roels
Journal:  BMC Vet Res       Date:  2010-05-21       Impact factor: 2.741

5.  A comparative study of modified confirmatory techniques and additional immuno-based methods for non-conclusive autolytic bovine spongiform encephalopathy cases.

Authors:  Rocío Sarasa; Dietmar Becher; Juan J Badiola; Marta Monzón
Journal:  BMC Vet Res       Date:  2013-10-18       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.